CA
NZ
UK
AU
IND
US
Vanda Pharmaceuticals Inc. has reported a significant decline in Q2 2026 revenue, directly impacted by a 66% drop in Hetlioz sales due to increasing generic competition and a delayed $7 million shipment, now expected to arrive in Q3. Despite this setback, the company's revenue …
The validating figures come as shares have climbed 36.3% year-to-date, indicating a growing investor confidence in the company's direction.
Canopy Growth Corporation reported a 13% increase in consolidated net revenue to $81.2 million for the fiscal first quarter ending June 30, 2026. This achievement contrasts with a consensus estimate of a net loss per share of $-0.03, compared to a loss of $-0.12 …
DENTSPLY SIRONA reported $898 million in net sales for the second quarter of 2026, representing a 4.1% decrease from $936 million in the same period last year. Despite this sales drop, the firm’s performance was strong against market expectations, with an adjusted EPS of …
DENTSPLY SIRONA reported $898 million in net sales for the second quarter of 2026, representing a 4.1% decrease from $936 million in the same period last year. Despite this sales drop, the firm’s performance was strong against market expectations, with an adjusted EPS of …
This result surpassed analysts' estimates, contributing positively to investor sentiment. The company's earnings per share (EPS) was reported at $-0.14, slightly better than the consensus expectation of $-0.16. Growth was largely driven by stronger demand for portable oxygen concentrators, particularly in international markets, with …
This performance fell in line with the consensus estimate of a loss per share of $-0.02, yet overall investor sentiment turned sour, with shares plunging 14% to $0.66. Year-to-date, SkinHealth's stock has declined 52.8%, reflecting growing investor skepticism amid ongoing operational challenges.
Falling profits at Novo Nordisk have triggered a rating downgrade, with Q2 earnings tumbling 70%. This sharp decline reflects operational issues and increasing competition that threaten the company's previously dominant position in diabetes and obesity treatments, notably its top-selling drug, semaglutide. As analysts adjust …
United-Guardian delivered a 10% lift in second‑quarter net sales, reaching $3,108,267, and a 16% jump in net income to $728,579, pushing earnings per share to $0.16. The surge reflects a 44% rise in cosmetic ingredient sales and a modest 1% gain in pharmaceutical revenue, …
Canopy Growth's fiscal Q1 2027 revenue increased 13%, reaching C$81.2 million, a performance driven by growth across its cannabis and Storz & Bickel business segments. The company reported a narrowed adjusted EBITDA loss of 59%, bringing it down to C$3.2 million as management reiterated …
Please wait processing your request...